Trials / Unknown
UnknownNCT05110807
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB3617 is a bromodomain and extra-terminal (BET) inhibitor that can competitively bind to bromodomains (BRDs) with Acetylated lysine(Kac) and block or partially block the role of KAc in subsequent gene transcription and regulation of chromatin structure, thereby playing an anti-tumor role.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3617 | TQB3617 is a BET inhibitor. |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2022-10-01
- Completion
- 2022-12-01
- First posted
- 2021-11-08
- Last updated
- 2022-02-14
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05110807. Inclusion in this directory is not an endorsement.